Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Super-enhancers (SEs) consist of multiple typical enhancers enriched at high density with
transcription factors, histone-modifying enzymes and cofactors. Oncogenic SEs promote …

Abstract N6-methyladenine (m6A) is the most predominant RNA modification, which has
been shown to be related to many types of cancers. However, understanding of its role in …

Abstract Lysine-specific demethylase 1 (LSD1) is a histone demethylase that promotes
stemness and cell survival in cancers such as prostate cancer. Most prostate malignancies …

Dysregulated glycolysis has been noted in several pathological processes characterized by
supporting cell proliferation. Nonetheless, the role of glycolysis reprogramming is not well …

Cancer arises following alterations at different cellular levels, including genetic and
epigenetic modifications, transcription and translation dysregulation, as well as metabolic …

The development of taxane resistance remains a major challenge for castration resistant
prostate cancer (CR-PCa), despite the effectiveness of taxanes in prolonging patient …

It is becoming increasingly clear that N6-methyladenosine (m6A) plays a key role in post-
transcriptional modification of eukaryotic RNAs in cancer. The regulatory mechanism of m6A …

Prostate cancer (PCa) is the most common malignant tumor and the second leading cause
of cancer-related mortality in men worldwide. Despite significant advances in PCa therapy …

Purpose PARP inhibitors have revolutionized the treatment landscape for advanced prostate
cancer (PCa) patients who harboring mutations in homologous recombination repair (HRR) …